| Ytd | -80.23% | |
| 1y | -51.63% |
| Open | 1.76 | Prev Close | 1.75 | Low | 1.73 | High | 1.82 | Mkt Cap | 119.58M |
| Vol | 842.62K | Avg Vol | 1.20M | EPS | -2.17 | P/E | -0.82 | Forward P/E | -3.53 |
| Beta | -0.28 | Short Ratio | 11.39 | Inst. Own | 83.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-14 | 50-d Avg | 1.78 | 200-d Avg | 6.18 | 1yr Est | 27.00 |
ENGN News
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzing
Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litiga
LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigat
enGene Therapeutics is rated Buy, trading below its $4.66/share cash floor despite weak Phase 2 data
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
LOS ANGELES--(BUSINESS WIRE)---- $ENGN--ENGN Investors Have Opportunity to Join enGene Therapeutics
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in H
enGene NASDAQ: ENGN reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEN
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims o
US stocks higher Thursday morning, Dow down 0.28%, Nasdaq up 0.50%, S&P 500 up 0.07%. Tech secto
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN or “enGene” or the “Compa
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasda
enGene Holdings Inc. (NASDAQ: ENGN - Get Free Report) has earned a consensus recommendation of "Mode
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company rep